LM-108 antibody and sintilimab
Phase 2Monoclonal antibody
LM-108 antibody and sintilimab is one of 37 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Anktiva
SSWOG Cancer Research Network
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
LM-108 antibody and sintilimab
SShanghai Pulmonary Hospital, Shanghai, China
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details